|
Press Releases |
|
 |
|
Thursday, May 23, 2024 |
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
Wednesday, May 22, 2024 |
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
Wednesday, May 15, 2024 |
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
Monday, May 13, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
GMG Announces Graphene Coating Patent Approval and Customer Case Study Successes
Sept 15, 2025 20:09 HKT/SGT
|
|
|
CTF Life+ Initiative Strengthens Company Connections with the Younger Generation
Sept 15, 2025 17:33 HKT/SGT
|
|
|
Focus Graphite and C4V Report Breakthrough Early Results Showing 26% Improvement in LFP Cathode Density Using Lac Knife Cathode Ultima
Sept 15, 2025 17:09 HKT/SGT
|
|
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sept 15, 2025 15:19 HKT/SGT
|
|
|
Toyota Launches Next-Generation New Mobility e-Palette
Sept 15, 2025 15:33 JST
|
|
|
Announcing the results of the 42nd Hong Kong Watch and Clock Design Competition
Sept 15, 2025 11:27 HKT/SGT
|
|
|
Submarine Networks World 2025 - the annual flagship event for the global subsea industry returns to Singapore in September.
Sept 15, 2025 08:00 HKT/SGT
|
|
|
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 12, 2025 15:08 JST
|
|
|
GR Yaris "Aero performance package" Set for Japan Launch
Sept 12, 2025 14:40 JST
|
|
|
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sept 12, 2025 14:19 JST
|
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 12, 2025 13:20 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sept 12, 2025 11:00 JST
|
|
|
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter
Sept 12, 2025 05:00 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Important High-Grade Copper and Gold Intercepts at Hat Polymetallic Deposit in Northwestern British Columbia
Sept 11, 2025 22:29 HKT/SGT
|
|
|
The 10th Belt and Road Summit concludes successfully
Sept 11, 2025 20:40 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|